Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,720 JPY | +0.67% | +1.49% | +17.70% |
May. 28 | Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview?? Monitoring System | CI |
May. 15 | Correction: Terumo’s Profit Up 47% in Fiscal 2024 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 37.26 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.45 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.70% | 25.62B | A- | ||
-2.26% | 187B | C+ | ||
+2.05% | 110B | C | ||
-1.31% | 69.54B | A | ||
+14.65% | 46.37B | B- | ||
-6.69% | 46.05B | B- | ||
+7.97% | 42.54B | B+ | ||
+18.60% | 30.72B | B | ||
-6.87% | 23.32B | B | ||
-10.63% | 22.92B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4543 Stock
- Ratings Terumo Corporation